- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05913713
HIIT dopo la chemioterapia per il cancro al seno
Allenamento ad intervalli ad alta intensità: ottimizzazione della terapia fisica per mitigare il rischio di malattie cardiovascolari dopo la chemioterapia per il cancro al seno
Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training compared to moderate-intensity continuous training on cardiovascular rehabilitation in breast cancer survivors.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32611
- Integrative Cardiovascular Physiology Laboratory, University of Florida
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- female patients based on biological sex
- 18 to 85 years of age
- diagnosis of primary, invasive, non-metastatic, stages I-III breast cancer
- completed chemotherapy for breast cancer (anthracycline, alkylating agent and/or taxane) more than 6 months but less than 18 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment and during study participation
- absence of contraindications to exercise or to participate in study
- study clinician approval
Exclusion Criteria:
- do not meet inclusion criteria
- scheduled to receive surgery or radiation therapy during the intervention period
- any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
- lymphedema stage ≥2 prior to study enrollment
- are pregnant
- current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: High Intensity Interval Training (HIIT)
Supervised home-based high-intensity interval training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks. |
Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period. After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises. |
|
Sperimentale: Moderate Intensity Continuous Training (MICT)
Supervised home-based moderate-intensity continuous training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks. |
Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period. After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises. |
|
Altro: Usual Care (UC)
Research participants will continue their habitual physical activity for the duration of the study. Once they complete the study, they will have the opportunity to perform supervised HIIT or MICT at home for 3 days/week for 12 weeks (research participants can choose either type of exercise). |
Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period. After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in brachial FMD
Lasso di tempo: Baseline, Following a 12-week intervention period, Following a 12-week observation period
|
Flow-mediated dilation (FMD) is an established non-invasive measure of endothelial function. Brachial artery FMD will be determined via ultrasonography in response to reactive hyperemia following 5-min forearm ischemia. |
Baseline, Following a 12-week intervention period, Following a 12-week observation period
|
|
Change in cardiac function (global longitudinal strain)
Lasso di tempo: Baseline, Following a 12-week intervention period, Following a 12-week observation period
|
Global longitudinal strain is a marker of acute subclinical cardiotoxicity and is recommended for monitoring cancer patients at risk of cancer therapy-related cardiac dysfunction. |
Baseline, Following a 12-week intervention period, Following a 12-week observation period
|
|
Percent completed vs. planned exercise frequency
Lasso di tempo: Throughout the 12 weeks of supervised home-based exercise training
|
The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise sessions/week. |
Throughout the 12 weeks of supervised home-based exercise training
|
|
Percent completed vs. planned exercise duration
Lasso di tempo: Throughout the 12 weeks of supervised home-based exercise training
|
The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise min/session. |
Throughout the 12 weeks of supervised home-based exercise training
|
|
Percent completed vs. planned exercise intensity
Lasso di tempo: Throughout the 12 weeks of supervised home-based exercise training
|
The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise intensity/session. |
Throughout the 12 weeks of supervised home-based exercise training
|
|
Number of participants who experience adverse events as defined by most recent CTCAE throughout the exercise intervention
Lasso di tempo: Throughout the 12 weeks of supervised home-based exercise training
|
To evaluate safety plans are in place for determination and monitoring of adverse events according to the most recent National Cancer Institute Common Terminology Criteria for Adverse Events. Classification for seriousness, expectedness, severity and relationship to study intervention will be based on the NIH provided definitions. |
Throughout the 12 weeks of supervised home-based exercise training
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Demetra Christou, PhD, University of Florida
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IRB202300460 -N
- 1R21AG078995-01A1 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .